Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP1 known ✓ | P03956 | 10/20 | 0.41 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.41 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.40 |
| ▸ | MMP7 known ✓ | P09237 | 6/20 | 0.39 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.54 |
| ▸ | MMP2 | P08253 | 16/20 | 0.41 |
| ▸ | MMP3 | P08254 | 11/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11130193 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL60916 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL1683449 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5183324 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5086708 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL875996 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL11576013 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL82688 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL59932 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A | |
| Hydrochloric Acid SCHEMBL5088573 | 1.00 | CSNK1E (0.54) | CSNK1EMMP2MMP3MMP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240353412-A1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2024-10-24 | — | — | US | claimed |
| US-11778794-B2 | Biopolymer-based electromagnetic interference shielding matertals | SOFTWARE DEFINED TECHNOLOGIES, INC (US) | 2023-10-03 | — | — | US | claimed |
| EP-4146765-B1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2023-07-05 | — | — | EP | claimed |
| EP-4146765-A1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN Medizinische Labordiagnostika AG (DE) | 2023-03-15 | — | — | EP | claimed |
| WO-2023006581-A1 | A METHOD AND REAGENTS FOR ENHANCING THE CHEMILUMINESCENT SIGNAL | EUROIMMUN MEDIZINISCHE LABORDIAGNOSTIKA AG (DE) | 2023-02-02 | — | — | WO | claimed |
| US-20210400855-A1 | BIOPOLYMER-BASED ELECTROMAGENTIC INTERFERRENCE SHIELDING MATERIALS | SOFTWARE DEFINED TECHNOLOGIES, INC. (US) | 2021-12-23 | — | — | US | claimed |
| US-8859769-B2 | Processes for preparing ticagrelor intermediate, 4,6-dichloro-5-nitro-2-(propylthio)pyrimidine | ACTAVIS GROUP PTC EHF (IS) | 2014-10-14 | — | — | US | claimed |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2013-03-21 | — | — | US | claimed |
| US-20130030176-A1 | PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE | ACTAVIS GROUP PTC EHF (IS) | 2013-01-31 | — | — | US | claimed |
| EP-2536695-A1 | IMPROVED PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE | Actavis Group Ptc Ehf (IS) | 2012-12-26 | — | — | EP | claimed |
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-09-15 | — | — | US | claimed |
| WO-2011101740-A1 | IMPROVED PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE | ACTAVIS GROUP PTC EHF (IS) | 2011-08-25 | — | — | WO | claimed |
| WO-2010023561-A9 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2011-08-04 | — | — | WO | claimed |
| EP-2334679-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | Actavis Group PTC EHF (IS) | 2011-06-22 | — | — | EP | claimed |
| EP-2268634-A2 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES | Actavis Group PTC EHF (IS) | 2011-01-05 | — | — | EP | claimed |
| WO-2010023561-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | ACTAVIS GROUP PTC EHF (IS) | 2010-03-04 | — | — | WO | claimed |
| WO-2009112954-A2 | PROCESSES FOR THE PREPARATION OF BOSENTAN AND RELATED COMPOUNDS USING NOVEL INTERMEDIATES | ACTAVIS GROUP PTC EHF (IS) | 2009-09-17 | — | — | WO | claimed |
| US-20260146171-A1 | COATED SUBSTRATES AND METHODS OF PREPARING THE SAME | PPG INDUSTRIES OHIO, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-4157312-A | QUATERNARY AMMONIUM, METAL CHELATE, SWEETENING | UOP INC. (US) | 1979-06-05 | — | — | US | disclosed |
| US-3988275-A | Concentrated latex of synthetic rubbers and the method for the preparation thereof | ASAHI KASEI KOGYO KABUSHIKI KAISHA (JA) | 1976-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110224437-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | MMP1 1644/4885HTR2A 355/4885KCNH2 240/4885 |
| US-20130072682-A1 | PROCESS FOR PREPARING VARENICLINE, VARENICLINE INTERMEDIATES, AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | TET2, NOX4, CYP3A7 | MMP1 1644/4885HTR2A 355/4885KCNH2 240/4885 |
| US-20260146171-A1 | COATED SUBSTRATES AND METHODS OF PREPARING THE SAME | PIEZO1, FTO, TAF1 | MMP1 181/4885HTR2A 1377/4885KCNH2 1601/4885 |
| US-20130030176-A1 | PROCESSES FOR PREPARING TICAGRELOR INTERMEDIATE, 4,6-DICHLORO-5-NITRO-2-(PROPYLTHIO)PYRIMIDINE | THPO, NUDT1, DPYD | MMP1 4380/4885HTR2A 577/4885KCNH2 2403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.